GDC-6599, a new TRPA1 antagonist with a promising preclinical PK and toxicity profile

Aug. 30, 2023

Researchers from Genentech Inc. presented preclinical data for the novel transient receptor potential ankyrin 1 (TRPA1) antagonist GDC-6599, currently in phase II development for respiratory indications.

BioWorld Science Conferences Respiratory

Today's news in brief

BioWorld

BioWorld briefs for July 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 18, 2025.

Blenrep misstep? ODAC cites tox, GSK dosing neglect in MM

BioWorld

The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as...

Adcom agrees with FDA: Otsuka’s PTSD treatment needs more study

BioWorld

In a 10-1 vote, the U.S. FDA’s Psychopharmacologic Drugs Advisory Committee said Otsuka Pharmaceutical Co. Ltd.’s studies of its combination post-traumatic stress...

Atai Therapeutics discovers new 5-HT2A receptor partial agonists

BioWorld Science

Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...